Holen Sie sich die Stockscreener-App
1.07
2.88%
0.03
Handel nachbörslich:
1.05
-0.02
-1.87%
Schlusskurs vom Vortag:
$1.04
Offen:
$1.04
24-Stunden-Volumen:
311.89K
Relative Volume:
0.64
Marktkapitalisierung:
$66.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.5815
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
+1.90%
1M Leistung:
-7.76%
6M Leistung:
-17.69%
1J Leistung:
-69.16%
1-Tages-Spanne:
$1.0171
$1.10
1-Wochen-Bereich:
$0.97
$1.10
52-Wochen-Spanne:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.07 | 64.43M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Is Pyxis Oncology Inc. trending in predictive chart modelsJuly 2025 PostEarnings & Stepwise Swing Trade Plans - Newser
Pyxis Oncology Inc. stock momentum explainedMarket Rally & Long-Term Growth Stock Strategies - Newser
Using data models to predict Pyxis Oncology Inc. stock movement2025 Analyst Calls & Entry Point Strategy Guides - Newser
Earnings visualization tools for Pyxis Oncology Inc.Trade Signal Summary & Free Real-Time Market Sentiment Alerts - Newser
Statistical indicators supporting Pyxis Oncology Inc.’s strength2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Custom strategy builders for tracking Pyxis Oncology Inc.2025 Volatility Report & Risk Managed Investment Signals - Newser
Heatmap analysis for Pyxis Oncology Inc. and competitors [July 2025 Drop Watch]Weekly Breakout Stock Alerts - Newser
Can Pyxis Oncology Inc. recover in the next quarterEarnings Growth Report & Pattern Based Trade Signal System - Newser
Earnings visualization tools for Pyxis Oncology Inc. [July 2025 Closing Moves]Short-Term Swing Trade Alerts - Newser
Visual analytics tools that track Pyxis Oncology Inc. performanceSmart Risk Entry Zone Technical Analysis - Newser
Pyxis Oncology (PYXS) Projected to Post Earnings on Wednesday - Defense World
Real time scanner hits for Pyxis Oncology Inc. explainedPredictable Income Summary for Long-Term Trades - Newser
How to integrate Pyxis Oncology Inc. into portfolio analysis toolsBreakout Watcher with Entry and Exit Alerts - Newser
Should you hold or exit Pyxis Oncology Inc. nowPattern Breakout Tracker with Screener Tools - Newser
How Pyxis Oncology Inc. stock performs during market volatilityWeekly Chart-Based Forecast for Traders - Newser
Pyxis Oncology Inc. stock prediction for this weekShort-Term Trade Setup with Forecast Insight - Newser
Pyxis Oncology Inc. stock chart pattern explainedTrend Confirmation Scanner with Entry Focus - Newser
Pyxis Oncology PYXS 2025Q2 Earnings Preview Downside Concerns Amid Revenue Uncertainty - AInvest
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Triple Digit Growth Focused Trade Plan - Newser
Will Pyxis Oncology Inc. outperform the marketFree Real Trader Watchlist of Hot Stocks - Newser
AI Trend Models Suggest Bounce for Pyxis Oncology Inc.Early Entry Picks Before News Breakout Reviewed - beatles.ru
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus Price Target from Analysts - Defense World
Pyxis Oncology Updates Phase 1 Trial Enrollment - The Globe and Mail
Pyxis Oncology shares rise 4.36% after-hours after announcing revisions to patient enrollment for Phase 1 clinical trial. - AInvest
Pyxis Oncology Updates Phase 1 Trial Enrollment: What You Need to Know - AInvest
Pyxis Oncology updates patient enrollment for Phase 1 trial of micvotabart pelidotin - Investing.com
How does Pyxis Oncology Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News
What are analysts’ price targets for Pyxis Oncology Inc. in the next 12 monthsBreakthrough capital growth - Jammu Links News
What are the technical indicators suggesting about Pyxis Oncology Inc.Unlock daily trading alerts for profits - Jammu Links News
Should I hold or sell Pyxis Oncology Inc. stock in 2025Outstanding capital returns - Jammu Links News
What makes Pyxis Oncology Inc. stock price move sharplyDynamic profit opportunities - Jammu Links News
Pyxis Oncology Inc. Stock Analysis and ForecastBuild capital through low-risk investments - Jammu Links News
What institutional investors are buying Pyxis Oncology Inc. stockFastest return on investment - Jammu Links News
What is Pyxis Oncology Inc. company’s growth strategyInvest smarter with expert stock picks - Jammu Links News
We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - uk.finance.yahoo.com
Pyxis Oncology Inc. Consolidation Zone May Signal AccumulationLow Capital High Return Stock Plans Reviewed - metal.it
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):